Your browser doesn't support javascript.
loading
Targeting resident memory T cell immunity culminates in pulmonary and systemic protection against Brucella infection.
Wang, Hongbin; Hoffman, Carol; Yang, Xinghong; Clapp, Beata; Pascual, David W.
Affiliation
  • Wang H; Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America.
  • Hoffman C; Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America.
  • Yang X; Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America.
  • Clapp B; Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America.
  • Pascual DW; Department of Infectious Diseases and Immunology, University of Florida, Gainesville, Florida, United States of America.
PLoS Pathog ; 16(1): e1008176, 2020 01.
Article de En | MEDLINE | ID: mdl-31951645
ABSTRACT
Brucellosis remains the most common zoonotic disease globally. Currently no vaccines for humans exist, and conventional brucellosis vaccines for livestock fail to confer complete protection; hence, an improved vaccine is needed. Although Brucella infections primarily occur following a mucosal exposure, vaccines are administered parenterally. Few studies have considered mucosal vaccinations, or even targeting of tissue-resident memory T (TRM) cells. TRM cells protect against viral infections, but less is known of their role in bacterial infections, and even less for brucellosis. Oral prime, nasal boost with a newly developed Brucella abortus double mutant (znBAZ) confers nearly complete protection against pulmonary challenge with wild-type (wt) B. abortus 2308, and its protective efficacy is >2800-fold better than the RB51 vaccine. Vaccination with znBAZ potently stimulated CD8+ T cells, whereas mucosal vaccination with RB51 induced mostly CD4+ T cells. Subsequent analysis revealed these pulmonary CD44+ CD69+ CD8+ T cells to be either CD103+ or CD103- TRM cells, and these sequestered to the lung parenchyma as CXCR3lo and to the airways as CXCR3hi. Both CD8+ TRM subsets contained single-positive IFN-γ and TNF-α, as well as, polyfunctional cells. IL-17-producing CD8+ TRM cells were also induced by znBAZ vaccination, but in vivo IL-17 neutralization had no impact upon protection. In vivo depletion of CD4+ T cells had no impact upon protection in znBAZ-vaccinated mice. In contrast, CD4+ T cell depletion reduced RB51's protective efficacy in spleens and lungs by two- and three-logs, respectively. Although anti-CD8 mAb-treated znBAZ-vaccinated mice showed a significantly reduced pulmonary efficacy, this treatment failed to completely deplete the lung CD8+ T cells, leaving the CD103+ and CD103- CD8+ TRM cell ratios intact. Only znBAZ-vaccinated CD8-/- mice were fully sensitive to pulmonary challenge with virulent wt B. abortus 2308 since CD8+ TRM cells could not be induced. Collectively, these data demonstrate the key role of mucosal vaccination for the generation of CD8+ TRM cells in protecting against pulmonary challenge with virulent B. abortus.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Brucella abortus / Brucellose / Vaccin antibrucellique / Lymphocytes T CD8/ / Mémoire immunologique / Maladies pulmonaires Limites: Animals Langue: En Journal: PLoS Pathog Année: 2020 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Brucella abortus / Brucellose / Vaccin antibrucellique / Lymphocytes T CD8/ / Mémoire immunologique / Maladies pulmonaires Limites: Animals Langue: En Journal: PLoS Pathog Année: 2020 Type de document: Article Pays d'affiliation: États-Unis d'Amérique